Lead investigator says tisagenlecleucel has changed natural history of DLBCL
January 23, 2019
Richard Maziarz, M.D., discusses the durability of gene transfer therapy treatment for patients with a form of lymphoma; “I would say that with this therapy, the natural history of lymphoma has just changed.”